Analyst Price Targets — NUVB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 7, 2026 12:24 pm | Leonid Timashev | RBC Capital | $20.00 | $6.40 | TheFly | Nuvation Bio price target raised to $20 from $19 at RBC Capital |
| July 27, 2026 12:26 pm | — | H.C. Wainwright | $21.00 | $6.76 | TheFly | Nuvation Bio price target raised to $21 from $17 at H.C. Wainwright |
| July 7, 2026 11:31 am | — | RBC Capital | $19.00 | $5.60 | TheFly | Nuvation Bio price target lowered to $19 from $20 at RBC Capital |
| January 27, 2026 1:20 pm | — | Truist Financial | $13.00 | $5.66 | TheFly | Nuvation Bio price target raised to $13 from $11 at Truist |
| January 21, 2026 11:35 am | Leonid Timashev | RBC Capital | $12.00 | $6.01 | TheFly | Nuvation Bio price target raised to $12 from $9 at RBC Capital |
| January 12, 2026 1:51 pm | — | H.C. Wainwright | $17.00 | $6.52 | TheFly | Nuvation Bio price target lowered to $17 from $18 at H.C. Wainwright |
| January 7, 2026 5:45 am | Michael Yee | UBS | $10.00 | $8.49 | StreetInsider | UBS Starts Nuvation Bio Inc (NUVB) at Neutral |
| December 11, 2025 11:25 am | — | H.C. Wainwright | $18.00 | $7.89 | TheFly | Nuvation Bio price target raised to $18 from $10 at H.C. Wainwright |
| December 1, 2025 11:34 am | Robert Burns | H.C. Wainwright | $10.00 | $8.04 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Nuvation Bio Inc (NUVB) |
| November 24, 2025 12:21 pm | — | Truist Financial | $11.00 | $6.99 | TheFly | Nuvation Bio initiated with a Buy at Truist |
Latest News for NUVB
NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D.
Nuvation Bio (NUVB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Designation offers pathway to expedite regulatory review, pending positive data, and reinforces safusidenib's potential to address significant medical needs for patients with IDH1-mutant glioma Pivotal Phase 3 SIGMA study enrollment underway NEW YORK, Aug. 20, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today…
The mean of analysts' price targets for Nuvation Bio (NUVB) points to a 105.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Nuvation Bio (NYSE: NUVB - Get Free Report) and Pathfinder Cell Therapy (OTCMKTS:PFND - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation. Insider and Institutional Ownership 61.7% of Nuvation
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NUVB.
U.S. House Trading
No House trades found for NUVB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.